Open-Label Uridine for Treatment of Depressed Adolescents with Bipolar Disorder
Quick navigation
Link to full study
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3080753/
Conclusion of this study
In this pilot case series, uridine was efficacious and well tolerated by study participants. Rapid onset of action may be a distinguishing feature of uridine. Open-label studies are an initial step in testing a novel intervention, and these findings should be considered preliminary. Uridine should not enter clinical practice as a primary treatment for depressed adolescents with bipolar disorder until randomized placebo-controlled trials have been performed to confirm its efficacy.
Supplements analyzed in this study
Health conditions analyzed in this study
Functions related to this study
Body systems related to this study